custom image

Myeloid Cells and Innate Immunity in Solid Tumors

September 21-23, 2020 | 10:00AM EDT | 2:00PM UTC*
*Program is in development and subject to change

The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. This virtual conference will present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this meeting will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The program will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.

Program is intended for scientific researchers and clinical audiences.

Join us for this landmark virtual event, brought to you by Keystone Symposia.


Registration for this meeting is now closed.


Scholarships: Passed
Abstract Submission: Passed


Program Details

Speaking at this eSymposia

Simon T. Barry

AstraZeneca, UK

Vincenzo Bronte

University of Verona, Italy

David A. Cheresh

University of California, San Diego, USA

Lisa M. Coussens

Oregon Health & Science University, USA

David G. DeNardo

Washington University Medical School, USA

Mikala Egeblad

Cold Spring Harbor Laboratory, USA

Dmitry I. Gabrilovich

AstraZeneca, USA

Florent Ginhoux

Singapore Immunology Network, Singapore

Jennifer Guerriero

Dana-Farber Cancer Institute, USA

Nagy A. Habib

Imperial College London and MiNA Therapeutics, UK

Diana Hargreaves

The Salk Institute for Biological Studies, USA

Catherine Hedrick

La Jolla Institute for Immunology, USA

Claudia Jakubzick

Dartmouth College, USA

Rosandra Natasha Kaplan

NCI, National Institutes of Health, USA

Miriam Merad

Mount Sinai School of Medicine, USA

Shruti Naik

New York University, USA

Brenda C. O'Connell

Infinity Pharmaceuticals, Inc., USA

Jeffrey W. Pollard

Queen's Medical Research Institute, UK

Gwendalyn J. Randolph

Washington University, USA

Minna Roh-Johnson

University of Utah, USA

Michael C. Schmid

Liverpool University, UK

Limin Shang

Light Chain Bioscience, Switzerland

Antonio Sica

University of Eastern Piedmont, Italy

Jo A. Van Ginderachter

VIB-Vrije Universiteit Brussel, Belgium

Judith A. Varner

University of California, San Diego, USA

Robert H. Vonderheide

University of Pennsylvania, USA

Weiping Zou

University of Michigan, USA


custom image

custom image

custom image

Additional Support

custom image

custom image

Funding for this conference was made possible (in part) by 1R13CA254451-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Media In-Kind Sponsors




custom image

The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.

Donate to Keystone Symposia

custom image